Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer.
- Author:
Sang Hee KIM
1
;
Jihye CHOI
;
Chan Sub PARK
;
Hyun Ah KIM
;
Woo Chul NOH
;
Min Ki SEONG
Author Information
- Publication Type:Original Article
- Keywords: Aromatase inhibitors; Breast neoplasms; Gonadotropin-releasing hormone; Goserelin; Premenopause
- MeSH: Aromatase Inhibitors; Aromatase*; Breast Neoplasms*; Breast*; Follow-Up Studies; Gonadotropin-Releasing Hormone*; Goserelin; Humans; Lutein*; Medical Records; Premenopause; Retrospective Studies
- From: Journal of Breast Disease 2018;6(2):46-51
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. METHODS: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. RESULTS: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. CONCLUSION: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.
